Clinical Trials Browser

INDUSTRY × Expanded_access × Sarcoma × Clear all

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT05974410 2025-10-02

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Available

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Brain Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Glioblastoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT06751524 2024-12-30

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Available

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT03994627 2024-12-16

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Approved for marketing

Sarcoma

NCT03874455 2024-03-22

Tazemetostat Expanded Access Program for Adults With Solid Tumors

No longer available

GenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Renal Cell, Chondrosarcoma, Sarcoma, Sarcoma, Synovial, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05612191 2022-11-28

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Available

Sarcoma

NCT00210665 2017-10-10

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

No longer available

Sarcoma

NCT02570412 2015-10-22

Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

No longer available

Sarcoma

Clinical Trials

KEAP

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy